Tag: ACADIA Pharmaceuticals
-
Investors May Want to Use ACADIA Weakness as Opportunity
Don’t write off ACADIA Pharmaceuticals (ACAD) just yet. In early March, the stock gapped from about $45.50 to $20.63. All after the US FDA rejected its drug to treat hallucinations and delusions associated with dementia-related psychosis (DRP), as noted by the company. “Despite prior agreements with the Division of Psychiatry regarding the pivotal Phase 3 HARMONY study…